Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential.
Lin Z, Wu Y, Xu Y, Li G, Li Z, Liu T. · 2022
Read Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential. by Lin Z, Wu Y, Xu Y, Li G, Li Z, Liu T. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9468526.txt.
Introduction
Lin and co-authors review how exosomes from mesenchymal stem cells drive cancer therapy resistance. These stem cells can form bone, fat, and cartilage cells. Tumors trade signals with them inside the tumor setting. Tiny vesicles called exosomes carry much of that traffic.
The review first covers how exosomes form and what they carry. It then shows their role treatment by treatment. Chemotherapy resistance is one major theme. Targeted therapy and radiotherapy resistance follow. Immunotherapy resistance is covered too. The vesicles shift the tumor microenvironment in the tumor's favor. The authors then flip the story. Engineered exosomes could deliver drugs or restore drug sensitivity. They could also help repair radiation damage. Open problems in dosing and safety close the review.
Catalog record
| CREATOR | Lin Z, Wu Y, Xu Y, Li G, Li Z, Liu T. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 84 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential By Zhengjun Lin, Yanlin Wu, Yiting Xu, Guoqing Li, Zhihong Li, Tang Liu Published in: Molecular Cancer DOI: 10.1186/s12943-022-01650-5 ABSTRACT Mesenchymal stem cells (MSCs) are multipotent stromal cells that can be obtained from various human tissues and organs. They can differentiate into a wide range of cell types, including osteoblasts, adipocytes and chondrocytes, thus exhibiting great potential in regenerative medicine. Numerous studies have indicated that MSCs play critical roles in cancer biology. The crosstalk between tumour cells and MSCs has been found to regulate many tumour behaviours, such as proliferation, metastasis and epithelial-mesenchymal transition (EMT). Multiple lines of evidence have demonstrated that MSCs can secrete exosomes that can modulate the tumour microenvironment and play important roles in tumour development. Notably, very recent works have shown that mesenchymal stem cell-derived exosomes (MSC-derived exosomes) are critically involved in cancer resistance to chemotherapy agents, targeted-therapy drugs, radiotherapy and immunotherapy. In this review, we systematically summarized the emerging roles and detailed molecular mechanisms of MSC-derived exosomes in mediating cancer therapy resistance, thus providing novel insights into the clinical applications of MSC-derived exosomes in cancer management. BACKGROUND Cancer is a major disease and the leading cause of mortality worldwide [1]. Although several treatment approaches, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy have been developed and effectively improved patients’ prognoses, both intrinsic and acquired therapy resistance contribute to the reduction of therapeutic effectiveness, thus resulting in poor outcomes of cancer patients [2, 3]. The mechanisms of cancer therapy resistance are complicated and multifaceted, including decreased uptake and/or increased efflux of drugs, the inhibition of apoptosis-related signalling pathways, activation of cancer stem cells (CSCs), enhanced DNA damage repair, loss of cell cycle control, as well as physical barriers preventing therapeutic drugs from entering the tissue and exerting their effects [4–6]. Nevertheless, the detailed mechanisms underlying anticancer therapy resistance are still unclear. Identifying the key mediators of cancer therapy resistance could help us to understand the development of therapy resistance, and these mediators play considerable roles in the prediction and reversion of anticancer therapy resistance. Mesenchymal stem cells (MSCs) are multipotent stem cells that can self-renew and differentiate into multilineage cells [7]. MSCs can be obtained from a variety of human tissues and organs, such as the bone marrow, fat tissue, brain, lung, and pancreas [7]. Moreover, emerging evidence has highlighted the regulatory roles of MSCs in both physiological and pathological conditions [8]. MSCs have the innate affinity to home to tumour sites and can modulate multiple biological processes related to cancer, such as metastasis, angiogenesis and epithelial-mesenchymal transition (EMT) [9, 10]. Notably, MSCs can secrete exosomes that can interact with diverse recipient cells to affect diverse biological behaviours of targeted cells, thereby modulating physiological homeostasis and/or the progression of human diseases [11]. Exosomes are nanosized membrane vesicles 40–160 nm in diameter that can be secreted by diverse cell types [12, 13]. Exosomes comprise complex contents, such as nucleic acids including DNA, mRNAs, and noncoding RNAs (ncRNAs), lipids, and various proteins [14, 15]. The major function of exosomes is modulating intercellular communication between diverse cell types by transferring multiple molecules, which mediate various cellular processes in both physiological and pathological conditions [16, 17]. Notably, numerous works have found that MSC-derived exosomes can function as critical modulators in the tumour microenvironment, and mediate the pathogenesis of various human cancers [18, 19]. Interestingly, MSC-derived exosomes have been found to play an essential role in cancer therapy resistance, including chemoresistance, targeted therapy resistance, radiotherapy resistance and immunotherapy resistance [20–22]. Furthermore, MSC-derived exosomes have been exploited as a novel therapeutic strategy in antitumour treatment due to their various advantages, such as biocompatibility, promising potential for modification, and lack of cytotoxicity [20–22]. For instance, MSC-derived exosomes show great potential for the delivery of anticancer agents because they can enhance their efficacy with low toxicity. Additionally, a great number of investigations have indicated that MSC-derived exosomes transfected with synthetic miRNAs can effectively enhance the sensitivity of cancer cells to chemotherapeutic drugs [18, 20]. In this review, we performed a systematic review of the pivotal roles of MSC-derived exosomes in mediating cancer therapy resistance as well as the complex mechanisms by which MSC-derived exosomes enhance or weaken anticancer-therapy resistance. Meanwhile, we also discussed the clinical applications of MSC-derived exosomes as novel therapeutic strategies for enhancing drug sensitivity, drug delivery vehicles and radiation-induced damage repair in cancer management. OVERVIEW OF MSC-DERIVED EXOSOMES Biogenesis of exosomes Exosomes are of endosomal origin and derived from lipid raft microdomains in the plasma membrane, with a diameter ranging in size from 40 to 160 nm and a density of 1.15–1.19 g/mL in sucrose gradients [23–25]. Exosomes are characterized as having a round morphology with heterogeneous sizes under a transmission electron microscope [26]. Exosomes are derived from a sequential process, mainly including the dual invagination of the plasma membrane, and the formation of intracellular multivesicular bodies (MVBs) that contain intraluminal vesicles (ILVs) (Fig. 1a) [27]. The biogenesis of exosomes starts with the invagination of primary endocytic vesicles encysting proteins from the cell surface and extracellular environments, which form the early-sorting endosomes (ESEs). Some ESEs are returned to the plasma membrane by endosome recycling, whereas other ESEs can induce the formation of late sorting endosomes (LSEs), and invagination of LSEs gives rise to ILVs [27]. This process contributes to the modification of cargos in the future resulting exosomes and the subsequent formation of MVBs. While some MVBs will be degraded by autophagosomes or lysosomes, others can fuse with the plasma membrane and then release ILVs into the extracellular environment as exosomes [28].Fig. 1Overview of MSC-derived exosomes. A Biogenesis of exosomes. The biogenesis of exosomes comprises endocytosis, MVB formation, and exosome secretion into the extracellular microenvironment through merging with the plasma membrane. B Characteristics and contents of exosomes. C Exosome purification methods A variety of proteins have been found to modulate the biogenesis of exosomes. Endosomal-sorting complex required for transport (ESCRT) proteins (ESCRT-0, ESCRT-I, ESCRT-II and ESCRT-III) are recognized as crucial mediators of ILV formation [29]. They can sort protein cargoes, induce membrane budding and sever membrane necks from their inner face with accessory proteins including Alix, VPS4 and VTA1 [30]. During the process of ILV biogenesis, protein cargoes captured into ILVs are principally characterized by ubiquitin, and the ESCRT-0 complex recognizes and obtains ubiquitinated proteins in the late endosome membrane [31, 32]. Then, cargoes are handed over to ESCRT-I, followed by the recruitment of ESCRT-II, which comprises a ubiquitin-binding and PtdIns3P-binding GLUE domain [29]. ESCRT-I and ESCRT-II complexes have strong recognition domains with high affinity for ubiquitinated substrates, and are responsible for shapping the membrane into buds, but it is still unknown whether ESCRT-I and ESCRT-II bind ubiquitylated cargoes sequentially or coordinately [33, 34]. ESCRT-III separates the vesicles from the cytoplasmic membrane to form MVBs, and promotes the deubiquitination of cargo proteins by deubiquitylating enzymes (DUBs) before ILV formation [14, 35]. Finally, ATPase induces the membrane scission and vacuolar protein sorting 4 (VPS4) participates in recycling all ESCRT molecules [36, 37]. The ubiquitinated proteins are critically involved in ESCRT-dependent cargo sorting and ILV formation, and E3 ubiquitin ligases and deubiquitylating enzymes have been identified to modulate the localization